Zobrazeno 1 - 10
of 61
pro vyhledávání: '"amatuximab"'
Autor:
Fumihiko Matsuzawa, Hirofumi Kamachi, Tatsuzo Mizukami, Takahiro Einama, Futoshi Kawamata, Yuki Fujii, Moto Fukai, Nozomi Kobayashi, Yutaka Hatanaka, Akinobu Taketomi
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-16 (2021)
Abstract Background Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antibody targeting mesothe
Externí odkaz:
https://doaj.org/article/59a5ff8880764bcdb8c4c420ec5d8690
Autor:
Moto Fukai, Yuki Fujii, Fumihiko Matsuzawa, Hirofumi Kamachi, Akinobu Taketomi, Tatsuzo Mizukami, Nozomi Kobayashi
Publikováno v:
Investigational New Drugs. 39:1256-1266
Amatuximab is a promising therapeutic antibody targeting mesothelin, a 40-kDa glycoprotein that is highly expressed in pancreatic cancer. We investigated the effectiveness of early amatuximab treatment, imitating an adjuvant chemotherapy setting, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::309d12a628b932c063f5aebe1a26f3f7
https://doi.org/10.1007/s10637-021-01118-1
https://doi.org/10.1007/s10637-021-01118-1
Autor:
Tatsuzo Mizukami, Nozomi Kobayashi, Yuki Fujii, Fumihiko Matsuzawa, Futoshi Kawamata, Hirofumi Kamachi, Takahiro Einama, Akinobu Taketomi, Yutaka Hatanaka
Publikováno v:
Oncotarget
Pancreatic cancer often has a very poor prognosis, even after complete resection. The recurrence of hepatic and peritoneal metastases is an important prognostic factor; therefore, the development of improved adjuvant therapy is urgently required. Mes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5367747b7bee9efcf5e79dc96970d867
https://doi.org/10.18632/oncotarget.26117
https://doi.org/10.18632/oncotarget.26117
Autor:
Erin N. Ross, J. Bradford Kline, Luigi Grasso, Nicholas C. Nicolaides, Charles Schweizer, Wenquan Wang, Elizabeth B. Somers, Shawn Fernando, Raffit Hassan
Publikováno v:
Cancer Biology & Therapy
The tumor-shed antigen CA125 has recently been found to bind certain monoclonal antibodies (mAbs) and suppress immune-effector mediated killing through perturbation of the Fc domain with CD16a and CD32a Fc-γ activating receptors on immune-effector c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc511129c7a66e107ec61f2e75bbc53
https://doi.org/10.1080/15384047.2018.1449614
https://doi.org/10.1080/15384047.2018.1449614
Amatuximab is a promising therapeutic antibody targeting mesothelin, a 40-kDa glycoprotein that is highly expressed in pancreatic cancer. We investigated the effectiveness of early amatuximab treatment, imitating an adjuvant chemotherapy setting, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f224aa33be2b416332e2ba0115bf89f2
https://doi.org/10.21203/rs.3.rs-322672/v1
https://doi.org/10.21203/rs.3.rs-322672/v1
Autor:
Akinobu Taketomi, Yutaka Hatanaka, Takahiro Einama, Fumihiko Matsuzawa, Moto Fukai, Tatsuzo Mizukami, Hirofumi Kamachi, Futoshi Kawamata, Nozomi Kobayashi, Yuki Fujii
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-16 (2021)
BMC Cancer
BMC Cancer
Background Mesothelin is a 40-kDa glycoprotein that is highly overexpressed in various types of cancers, however molecular mechanism of mesothelin has not been well-known. Amatuximab is a chimeric monoclonal IgG1/k antibody targeting mesothelin. We r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d34bb89d3ad14f586a0720d130b9b01
https://doi.org/10.1186/s12885-020-07722-3
https://doi.org/10.1186/s12885-020-07722-3
Autor:
Sara Cecco, Paolo Baldo
Publikováno v:
OncoTargets and therapy
Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted in 1992 after the immunization of mice with a human ovarian cancer (OC) cell line and cloned in 1996, MSLN seems to be involved in cell adhesion and metastasi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e51dff0f640ff1d297ac327f7de8db4f
https://doi.org/10.2147/ott.s145105
https://doi.org/10.2147/ott.s145105
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
OncoTargets and Therapy, Vol Volume 10, Pp 5337-5353 (2017)
Paolo Baldo, Sara Cecco Pharmacy Unit, Directorate Department, CRO Aviano-IRCCS National Cancer Institute, Aviano, Italy Abstract: Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted in 1992 after the immunizat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::775975c0ff9c510c834e4d6b9fb3ad93
https://www.dovepress.com/amatuximab-and-novel-agents-targeting-mesothelin-for-solid-tumors-peer-reviewed-article-OTT
https://www.dovepress.com/amatuximab-and-novel-agents-targeting-mesothelin-for-solid-tumors-peer-reviewed-article-OTT